Literature DB >> 20939697

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

Paolo Anderlini, Sandra A Acholonu, Grace-Julia Okoroji, Roland E Bassett, Elizabeth J Shpall, Muzaffar H Qazilbash, Uday R Popat, Laura L Worth, Sergio A Giralt, Richard E Champlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20939697      PMCID： PMC4238067          DOI： 10.3109/10428194.2010.524328

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

Authors:  H Joachim Deeg; Barry E Storer; Michael Boeckh; Paul J Martin; Jeannine S McCune; David Myerson; Shelly Heimfeld; Mary E Flowers; Claudio Anasetti; Kristine C Doney; John A Hansen; Hans-Peter Kiem; Richard A Nash; Paul V O'Donnell; Jerald P Radich; Brenda M Sandmaier; Bart L Scott; Mohamed L Sorror; E Houston Warren; Robert P Witherspoon; Ann Woolfrey; Frederick R Appelbaum; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

3.  Epstein-Barr virus-associated, CD20- polyclonal lymphoproliferative disorder after matched unrelated donor marrow transplantation.

Authors:  P Anderlini; J R Valbuena; R E Champlin; C E Bueso-Ramos
Journal:  Bone Marrow Transplant       Date:  2004-11       Impact factor: 5.483

4.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

Authors:  A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

5.  Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

Authors:  S M O'Brien; H M Kantarjian; J Cortes; M Beran; C A Koller; F J Giles; S Lerner; M Keating
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

6.  Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.

Authors:  Ramaprasad Srinivasan; Yoshiyuki Takahashi; J Philip McCoy; Igor Espinoza-Delgado; Colleen Dorrance; Takehito Igarashi; Andreas Lundqvist; A John Barrett; Neal S Young; Nancy Geller; Richard W Childs
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

7.  Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.

Authors:  J-H Lee; S-J Choi; J-H Lee; Y-S Lee; M Seol; S-G Ryu; J-S Lee; W-K Kim; K-H Lee
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483

8.  Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.

Authors:  H J Kang; H Y Shin; H S Choi; H S Ahn
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

9.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.

Authors:  Marcos de Lima; Athanasios Anagnostopoulos; Mark Munsell; Munir Shahjahan; Naoto Ueno; Cindy Ippoliti; Borje S Andersson; James Gajewski; Daniel Couriel; Jorge Cortes; Michele Donato; Joyce Neumann; Richard Champlin; Sergio Giralt
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 10.  Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Authors:  J Styczynski; H Einsele; L Gil; P Ljungman
Journal:  Transpl Infect Dis       Date:  2009-06-23       Impact factor: 2.228
View more
  6 in total

1.  Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.

Authors:  Asha Pillai; Christine Hartford; Chong Wang; Deqing Pei; Jie Yang; Ashok Srinivasan; Brandon Triplett; Mari Dallas; Wing Leung
Journal:  Pediatr Transplant       Date:  2011-07-15

2.  A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.

Authors:  Masahiro Ashizawa; Yu Akahoshi; Hirofumi Nakano; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako; Shun-Ichi Kimura; Misato Kikuchi; Hideki Nakasone; Shinichi Kako; Junya Kanda; Rie Yamazaki; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

3.  Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Authors:  Paolo Anderlini; Juan Wu; Iris Gersten; Marian Ewell; Jakob Tolar; Joseph H Antin; Roberta Adams; Sally Arai; Gretchen Eames; Mitchell E Horwitz; John McCarty; Ryotaro Nakamura; Michael A Pulsipher; Scott Rowley; Eric Leifer; Shelly L Carter; Nancy L DiFronzo; Mary M Horowitz; Dennis Confer; H Joachim Deeg; Mary Eapen
Journal:  Lancet Haematol       Date:  2015-09-02       Impact factor: 18.959

4.  Cyclophosphamide and fludarabine monophosphate dose optimization for the non-myeloablative condition in non-human primates to induce transient mixed chimerism via bone marrow transplantation.

Authors:  Yeongbeen Kwon; Kyo Won Lee; Hyojun Park; Jin Kyung Son; JongHyun Lee; Chan Woo Cho; Ghee Young Kwon; Jae Berm Park; Sung Joo Kim
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

5.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Authors:  Jakub Tolar; H Joachim Deeg; Sally Arai; Mitchell Horwitz; Joseph H Antin; John M McCarty; Roberta H Adams; Marian Ewell; Eric S Leifer; Iris D Gersten; Shelly L Carter; Mary M Horowitz; Ryotaro Nakamura; Michael A Pulsipher; Nancy L Difronzo; Dennis L Confer; Mary Eapen; Paolo Anderlini
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-27       Impact factor: 5.742

6.  Clinical outcomes in adult patients with aplastic anemia: A single institution experience.

Authors:  Prajwal Boddu; Guillermo Garcia-Manero; Farhad Ravandi; Gautam Borthakur; Elias Jabbour; Courtney DiNardo; Nitin Jain; Naval Daver; Naveen Pemmaraju; Paolo Anderlini; Simrit Parmar; Devendra Kc; Mary Akosile; Sherry A Pierce; Richard Champlin; Jorge Cortes; Hagop Kantarjian; Tapan Kadia
Journal:  Am J Hematol       Date:  2017-09-25       Impact factor: 10.047
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.